Avid Bioservices Inc (CDMO)

[InternetForumUser]

Steve Worsley
..
..
Vice President Business Development
Peregrine Pharmaceuticals
November 2013 – Present (2 years 9 months)Greater Los Angeles Area

(a $255MM biopharmaceutical No Longer a $255M Market Cap, has decreased a lot since his arrival. Maybe a $90MM now focused on immuno-oncology mAbs (Phase 3 NSCLC Phase 3 was a failure, MBC)
Responsible for all business development with top 20 pharmaceutical and biotech companies. Primary focus has been in the development and execution of five-year strategic business plan focused on worldwide licensing strategy for our Phase III mAb So far his 5 Year Business Plan has amounted to nothing and as for that licensing, what are they going to license? The trademark for a drug which has yet to be approved. As for the P3 MAB, well it failed. ; Bavituximab and in-licensing of key assetsKey Assets? Yeah how is that used in the same sentence with Peregrine. Oh.. I forgot Steve King is earning his pay and is a Asset. . Also lead for all licensing long-term alliance strategies for our Immuno Oncology collaborations with leading pharma’s and institutes.
• Negotiated/finalized Peregrines’ key research agreement w/Jedd Wolchok’s Lab at Memorial Sloan Kettering Cancer Center MSKCC for studies involving the combination of bavituximab with PD-1/L1 inhibitors
• Negotiated/finalized clinical agreement w/Astra Zeneca/MedImmune for NSCLC studies involving the combination of bavituximab with PD-L1 inhibitor: Durvalumab. Followed by 2nd contract 3 months later for add’l clinical combination studies.
• Negotiated/finalized research license and option agreement w/Affitech - for pre-clinical VEGF targeting mAbs (2014)